We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
- Recent LEGN Stock Price: $57.25
- Yearly Gain for LEGN stock: 18.60%
- Market Cap for LEGN stock: ―
- P/E Ratio for LEGN stock: -20.688
Will LEGN's stock price go up? Is there an accurate LEGN stock forecast available?
TipRanks.com reports that Legend Biotech currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $90.25. The target pricing ranges from a high LEGN forecast of $93 down to a low forecast of $87. Legend Biotech (LEGN)’s last closing stock price was $57.25 which would put the average price target at 57.22% upside.
In addition, TradingView issued a Buy rating for LEGN stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LEGN stock.
Other analysts covering LEGN include:
- Kostas Biliouris of BMO Capital issued a Buy rating with the price target of $90 on 1 day ago
- Kelly Shi of Jefferies issued a Buy rating with the price target of $93 on 1 day ago
- Justin Zelin of BTIG issued a Buy rating with the price target of $91 on 1 week ago
If you are wondering if LEGN is a good stock to buy, here are 3rd party ratings for LEGN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 19% (47 out of 251)
What is the sentiment on the street regarding Legend Biotech? (Current ratings compiled by TipRanks.com)
- News Sentiment for LEGN stock: Very Bullish
- Blogger Consensus for LEGN stock: Bullish
- Media Buzz for LEGN stock: Very Low
- Insider Signal for LEGN stock: ―
- Investor Sentiment for LEGN stock: Very Negative
- Hedge Fund signal for LEGN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on LEGN stock including scouring the social networks like LEGN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LEGN stock chart >>
Summary: Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
- Recent MDT Stock Price: $78.62
- Yearly Gain for MDT stock: -5.53%
- Market Cap for MDT stock: $99.47B
- P/E Ratio for MDT stock: 27.529
Will MDT's stock price go up? Is there an accurate MDT stock forecast available?
TipRanks.com reports that Medtronic currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $91.67. The target pricing ranges from a high MDT forecast of $90 down to a low forecast of $100. Medtronic (MDT)’s last closing stock price was $78.62 which would put the average price target at 13.88% upside.
In addition, TradingView issued a Strong sell rating for MDT stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MDT stock.
Other analysts covering MDT include:
- Josh Jennings of TD Cowen issued a Buy rating with the price target of $90 on 17 hours ago
- Joanne Wuensch of Citi issued a Hold rating with the price target of $85 on 2 days ago
- Travis Steed of Bank of America Securities issued a Buy rating with the price target of $100 on 4 days ago
If you are wondering if MDT is a good stock to buy, here are 3rd party ratings for MDT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 45% (139 out of 251)
What is the sentiment on the street regarding Medtronic? (Current ratings compiled by TipRanks.com)
- News Sentiment for MDT stock: Very Bullish
- Blogger Consensus for MDT stock: Bullish
- Media Buzz for MDT stock: Very High
- Insider Signal for MDT stock: Negative
- Investor Sentiment for MDT stock: Neutral
- Hedge Fund signal for MDT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on MDT stock including scouring the social networks like MDT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MDT stock chart >>
Summary: AVITA Medical Inc. is a regenerative medicine company. It engages in developing and commercializing a technology platform which enables point-of-care autologous skin restoration for multiple unmet needs. AVITA Medical Inc., formerly known as AVITA Therapeutics Inc., is based in VALENCIA, Calif.
- Recent RCEL Stock Price: $10.17
- Yearly Gain for RCEL stock: 74.65%
- Market Cap for RCEL stock: $321.94M
- P/E Ratio for RCEL stock: -9.403
Will RCEL's stock price go up? Is there an accurate RCEL stock forecast available?
TipRanks.com reports that Avita Medical currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.80. The target pricing ranges from a high RCEL forecast of $40 down to a low forecast of $19. Avita Medical (RCEL)’s last closing stock price was $10.17 which would put the average price target at 140.90% upside.
In addition, TradingView issued a Strong Buy rating for RCEL stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RCEL stock.
Other analysts covering RCEL include:
- Brooks O'Neil of Lake Street issued a Buy rating with the price target of $40 on 17 hours ago
- Ryan Zimmerman of BTIG issued a Buy rating with the price target of $20 on 1 day ago
- Josh Jennings of TD Cowen issued a Buy rating with the price target of $25 on 1 day ago
- Ross Osborn of Cantor Fitzgerald issued a Buy rating with the price target of $20 on 1 day ago
If you are wondering if RCEL is a good stock to buy, here are 3rd party ratings for RCEL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 26% (65 out of 251)
What is the sentiment on the street regarding Avita Medical? (Current ratings compiled by TipRanks.com)
- News Sentiment for RCEL stock: Very Bullish
- Blogger Consensus for RCEL stock: Bullish
- Media Buzz for RCEL stock: Low
- Insider Signal for RCEL stock: Neutral
- Investor Sentiment for RCEL stock: Very Negative
- Hedge Fund signal for RCEL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on RCEL stock including scouring the social networks like RCEL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RCEL stock chart >>
Summary: Agilent Technologies, Inc. is an original equipment manufacturer of a broad-based portfolio of test and measurement products serving multiple end markets. Recently, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG).The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers' representatives, telesales and electronic commerce, as necessary.
- Recent A Stock Price: $123.92
- Yearly Gain for A stock: -20.91%
- Market Cap for A stock: $33.11B
- P/E Ratio for A stock: 29.673
Will A's stock price go up? Is there an accurate A stock forecast available?
TipRanks.com reports that Agilent currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $127.80. The target pricing ranges from a high A forecast of $144 down to a low forecast of $100. Agilent (A)’s last closing stock price was $123.92 which would put the average price target at 4.77% upside.
In addition, TradingView issued a Sell rating for A stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on A stock.
Other analysts covering A include:
- Derik De Bruin of Bank of America Securities issued a Buy rating with the price target of $130 on 17 hours ago
- Luke Sergott of Barclays issued a Sell rating with the price target of $100 on 17 hours ago
- Daniel Arias of Stifel Nicolaus issued a Hold rating with the price target of $135 on 17 hours ago
- Daniel Brennan of TD Cowen issued a Buy rating with the price target of $144 on 1 day ago
If you are wondering if A is a good stock to buy, here are 3rd party ratings for A stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Top 35% (88 out of 251)
What is the sentiment on the street regarding Agilent? (Current ratings compiled by TipRanks.com)
- News Sentiment for A stock: Very Bullish
- Blogger Consensus for A stock: Bullish
- Media Buzz for A stock: Very High
- Insider Signal for A stock: ―
- Investor Sentiment for A stock: Very Negative
- Hedge Fund signal for A stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on A stock including scouring the social networks like A StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for A stock chart >>
Summary: Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif.
- Recent MYNZ Stock Price: $1.15
- Yearly Gain for MYNZ stock: -87.11%
- Market Cap for MYNZ stock: ―
- P/E Ratio for MYNZ stock: -0.623
Will MYNZ's stock price go up? Is there an accurate MYNZ stock forecast available?
TipRanks.com reports that Mainz Biomed B.V. currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.50. The target pricing ranges from a high MYNZ forecast of $8 down to a low forecast of $5. Mainz Biomed B.V. (MYNZ)’s last closing stock price was $1.15 which would put the average price target at 465.22% upside.
In addition, TradingView issued a Strong sell rating for MYNZ stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MYNZ stock.
Other analysts covering MYNZ include:
- Justin Walsh of JonesTrading issued a Buy rating with the price target of $8 on 17 hours ago
- Yi Chen of H.C. Wainwright issued a Buy rating with the price target of $5 on 1 day ago
If you are wondering if MYNZ is a good stock to buy, here are 3rd party ratings for MYNZ stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 19% (47 out of 251)
What is the sentiment on the street regarding Mainz Biomed B.V.? (Current ratings compiled by TipRanks.com)
- News Sentiment for MYNZ stock: Neutral
- Blogger Consensus for MYNZ stock: ―
- Media Buzz for MYNZ stock: Medium
- Insider Signal for MYNZ stock: ―
- Investor Sentiment for MYNZ stock: Very Negative
- Hedge Fund signal for MYNZ stock: No Signal
The stock market is extremely volatile, and you need to do your own research on MYNZ stock including scouring the social networks like MYNZ StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MYNZ stock chart >>
Summary: Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
- Recent BAYZF Stock Price: $37.17
- Yearly Gain for BAYZF stock: -35.12%
- Market Cap for BAYZF stock: $44.59B
- P/E Ratio for BAYZF stock: -9.029
Will BAYZF's stock price go up? Is there an accurate BAYZF stock forecast available?
TipRanks.com reports that Bayer currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $58.59. The target pricing ranges from a high BAYZF forecast of $98.56 down to a low forecast of $40.52. Bayer (BAYZF)’s last closing stock price was $37.17 which would put the average price target at 65.49% upside.
In addition, TradingView issued a Strong sell rating for BAYZF stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BAYZF stock.
Other analysts covering BAYZF include:
- Richard Vosser of J.P. Morgan issued a Hold rating with the price target of $51.47 on 1 day ago
- Emily Field of Barclays issued a Hold rating with the price target of $43.8 on 1 day ago
- Colin White of UBS issued a Buy rating with the price target of $98.56 on 1 day ago
If you are wondering if BAYZF is a good stock to buy, here are 3rd party ratings for BAYZF stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Bayer? (Current ratings compiled by TipRanks.com)
- News Sentiment for BAYZF stock: Neutral
- Blogger Consensus for BAYZF stock: ―
- Media Buzz for BAYZF stock: Very Low
- Insider Signal for BAYZF stock: ―
- Investor Sentiment for BAYZF stock: ―
- Hedge Fund signal for BAYZF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on BAYZF stock including scouring the social networks like BAYZF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BAYZF stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
